Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 261 participants.

Also called NCT03068130

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 261 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03068130
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Germany, Israel, Japan, Mexico, Netherlands, Philippines, Spain, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03068130. Allocation not applicable; no masking; primary purpose treatment. Start 2017-04-18 (actual); primary completion 2020-09-30 (actual). Results posted on 2023-10-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
Acronym
RANGER
Intervention (Drug)
Bardoxolone methyl
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct03068130
Content hash
7b2b69098925fc7aa98486cdd641a591c098cd1fc584a6b5f50f6d19a0a9b88c